A REVIEW: STATUS OF GENETIC MODULATED NONSMALL CELL LUNG CANCER TARGETS AND TREATMENT (CURRENT UPDATES IN DRUGS FOR NON-SMALL CELL LUNG CANCER TREATMENT)
Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.
2. Pfizer. Lung Cancer Fact Sheet. Pfizer; 2012.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 2008;83:584-94.
4. American Cancer Society. Lung Cancer (Non-Small Cell) What is non-small cell lung cancer ? Am Cancer Soc 2016;1:1-75.
5. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res 2016;5:288-300.
6. Gupta M, Dahiya J, Marwaha RK, Dureja H. Therapies in cancer treatment: An overview. Int J Pharm Pharm Sci 2015;7:1-9.
7. Karachaliou N, Mayo C, Costa C, MagrÃ I, Gimenez-Capitan A, Molina-Vila MA, et al. KRAS mutations in lung cancer. Clin Lung Cancer 2013;14:205-14.
8. Wang J, Song J, Gao Z, Huo X, Zhang Y, Wang W, et al. Analysis of gene expression profiles of non-small cell lung cancer at different stages reveals significantly altered biological functions and candidate genes. Oncol Rep 2017;37:1736-46.
9. Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014;464:347-58.
10. Johnson JL, Pillai S, Chellappan SP. Genetic and biochemical alterations in non-small cell lung cancer. Biochem Res Int 2012;2012:940405.
11. Risch A, Plass C. Lung cancer epigenetics and genetics. Int J Cancer 2008;123:1-7.
12. Lazarus DR, Ost DE. How and when to use genetic markers for nonsmall cell lung cancer. Curr Opin Pulm Med 2013;19:331-9.
13. Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget 2017;8:57680-92.
14. Black RC, Khurshid H. NSCLC: An update of driver mutations, their role in pathogenesis and clinical significance. R I Med J (2013) 2015;98:25-8.
15. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 2017;8:75712-26.
16. Lovly C, Horn L, Pao W. EGFR in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
17. Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: Current standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54.
18. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 2016;5:288-300.
19. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK, et al. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:15-31.
20. Bittner N, Ostoros G, GÃ©czi L. New treatment options for lung adenocarcinoma-in view of molecular background. Pathol Oncol Res 2014;20:11-25.
21. Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): A randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 2013;14:953-61.
22. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117-34.
23. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:3488-515.
24. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, McCormack R, Webster A, et al. First-line gefitinib in caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.
25. Pirker R, Filipits M. Cetuximab in non-small-cell lung cancer. Transl Lung Cancer Res 2012;1:54-60.
26. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C, et al. Cetuximab in advanced non-small cell lung cancer (NSCLC): The showdown? J Thorac Dis 2014;6:578-80.
27. Jain P, Khanal R, Sharma A, Yan F, Sharma N. Afatinib and lung cancer. Expert Rev Anticancer Ther 2014;14:1391-406.
28. Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, et al. Neratinib, an irreversible pan-erbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83.
29. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ,et al. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: Results of a phase I pharmacokinetic study. Clin Cancer Res 2006;12:4645-51.
30. Wang S, Song Y, Yan F, Liu D. Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors. Front Med 2016;10:383-8.
31. Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015;27:94-101.
32. Barnes TA, Oâ€™Kane GM, Vincent MD, Leighl NB. Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer. Front Oncol 2017;7:113.
33. Narita SN, Kanda S. Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer. Transl Cancer Res 2017;6:S1187-90.
34. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL, et al. Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci 2011;102:1822-8.
35. Lovly C, Horn L, Pao W. AKT1 in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
36. Vijayalakshmi R, Krishnamurthy A. Targetable driverâ€ mutations in non small cell lung cancer. Indian J Surg Oncol 2011;2:178-88.
37. Greulich H. The genomics of lung adenocarcinoma: Opportunities for targeted therapies. Genes Cancer 2010;1:1200-10.
38. LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol 2016;34:3803-15.
39. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated akt with GDC-0068, a novel selective akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013;19:1760-72.
40. Pal SK, Reckamp K, Yu H, Figlin RA. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2010;19:1355-66.
41. Lovly C, Horn L, Pao W. BRAF in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
42. de Langen AJ, Smit EF. Therapeutic approach to treating patients with BRAF-mutant lung cancer: Latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:46-58.
43. Baik CS, Myall NJ, Wakelee HA. TargetingBRAF-mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy. Oncologist 2017;22:786-96.
44. Caparica R, de Castro G Jr., Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, et al. BRAF mutations in non-small cell lung cancer: Has finally janus opened the door? Crit Rev Oncol Hematol 2016;101:32-9.
45. Ding X, Zhang Z, Jiang T, Li X, Zhao C, Su B, et al. Clinicopathologic characteristics and outcomes of chinese patients with non-small-cell lung cancer and BRAF mutation. Cancer Med 2017;6:555-62.
46. Luk PP, Yu B, Ng CC, Mercorella B, Selinger C, Lum T, et al. BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 2015;4:142-8.
47. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726-36.
48. Planchard D, Kim TM, Mazieres J, Quoix E, Riely G, Barlesi F, et al. Dabrafenib in BRAF V600E-mutant advanced non-small cell lung cancer: An open-label, single arm, multicenter, phase 2 trial. Lancet Oncol 2016;17:642-50.
49. Lovly C, Horn L, Pao W. ALK in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
50. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: A paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
51. Qin A, Gadgeel S. The current landscape of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer: Emerging treatment paradigms and future directions. Target Oncol 2017;12:709-18.
52. Iams WT, Lovly CM. Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer. Cancer J 2015;21:378-82.
53. Sequist LV, Neal JW. Personalized, Genotype-Directed Therapy for Advanced Non-Small Cell Lung Cancer. Uptodate; 2016. p. 1.
54. Lovly C, Horn L, Pao W. ROS1 in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
55. Bubendorf L, BÃ¼ttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, et al. Testing for ROS1 in non-small cell lung cancer: A review with recommendations. Virchows Arch 2016;469:489-503.
56. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
57. MaziÃ¨res J, RouviÃ¨re D, Milia JD, Filleron T, Zalcman G, Biondani P, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J Clin Oncol 2015;33:992-9.
58. FDA. FDA Expands Use of Advanced therapy for Non-Small Cell Lung Cancer. Am Assoc Cancer Res 2016;1:1.
59. Lovly C, Shi GC, Watson L, Horn P, Pohlmann LG. HER2 (ERBB2) in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
60. Peters S, Zimmermann S. Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res 2014;3:84-8.
61. Garrido-Castro AC, Felip E. HER2 driven non-small cell lung cancer (NSCLC): Potential therapeutic approaches. Transl Lung Cancer Res 2013;2:122-7.
62. Lovly C, Horn L, Pao W. KRAS in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
63. Blumenschein GR Jr., Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, et al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)â€ . Ann Oncol 2015;26:894-901.
64. Kim ES, Herbst RS, Wistuba II, Lee JJ Jr., Blumenschein GR, Tsao A, et al. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
65. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:57-61.
66. JÃ¤nne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47.
67. Lovly C, Horn L, Pao W. MEK1 (MAP2K1) in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
68. Stinchcombe TE, Johnson GL, Comprehensive L, Hill C, Comprehensive L, Hill C. MEK inhibition in non-small cell lung cancer. Lung Cancer 2014;86:121-5.
69. Lovly C, Horn L, Pao W. NRAS in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
70. Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol 2015;16:15.
71. Lovly C, Horn L, Pao W. PIK3CA in non-small cell lung cancer (NSCLC). Cancer Genome 2015;1:1.
72. Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/ AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol 2014;90:197-207.
73. Espinosa AJ. RET in Lung Cancer. Cancer Genome 2015;1:1.
74. Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, et al. Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. Lung Cancer 2016;93:43-6.
75. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007;12:191-200.
76. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
77. Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013;8:e43-4.
78. Solomon B. MET in non-small cell lung cancer (NSCLC)-My Cancer Genome. Cancer Genome 2015;1:1.
79. Riely G. RET in lung cancer. Cancer Genome 2013; 1:1.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.